The Effect of an Anorectic Agent (Mazindol) on Control of Obese Diabetics

Sanders, M.; Breidahl, H. D.

doi:10.5694/j.1326-5377.1976.tb130393.x

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A further analysis revealed us that in patients with comorbidities, only in 9 cases of minor adverse reactions, the basic problem worsened, whereas in patients with hypertension there were not reported increments in blood pressure and, only a subject of three, who had hypoglycemia was associated with concomitant administration of hypoglycemic agents. This profile of adverse events in Mexican patients is in line with the reported general set of adverse events and also with the statement that Mazindol is especially useful in patients with mild to moderate hypertension and diabetes mellitus [22,23]. Lucchetta et al in their meta-analysis study shows that Mazindol was not associated to major adverse reactions [34].…”

Section: Discussionsupporting

confidence: 83%

“…Several studies have documented the efficacy of Mazindol over placebo as an effective weight-reducing agent, which produces around 7 kg of weight loss, at twelve weeks [16][17][18][19][20][21]. In spite the several gastrointestinal, neurological, cardiovascular and endochrinological adverse events related with the use of Mazindol, it has been stated this product is especially useful in patients with mild-to-moderate hypertension, hyperlipidemia and diabetes mellitus, producing few adverse effects, and also in the treatment of patients with sleep disorders, as the incidence of central nervous stimulation is low with Mazindol [22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse Events Reported with the Use of Mazindol in Adult Obese Mexican Patients

Valle-Laisequilla¹,

Huerta-Cruz²,

Barranco-Garduño³

et al. 2018

Med Saf Glob Health

View full text Add to dashboard Cite

Background: Obesity is a pandemic disease. Lifestyle modifications as diet and exercise remain as the first-line intervention for obesity; however, many patients fail to attain adequate weight loss and require drug treatment. Mazindol is a short-term useful agent in the treatment of obesity, whose safety profile has not been analyzed in Mexican population. Objective: The current study was performed to investigate the reports of adverse events, received in the supplier laboratory for 8 years (2009-2016) with the purpose of determine potential issues of safety, related to Mazindol (MZ1®). Methods: Adverse events were arranged in frequency tables and stratified by intensity and causality. Subgroups of sex, age and BMI with a higher frequency of side-effects were identified, as well as the main comorbidities and concomitant medications. Results: One thousand three hundred eighty-six adverse events from 581 reports were received from 2009 to 2016. Most of reports were generated by patients in the fourth decade of life in both groups (25.5%). The most frequent adverse events were dry mouth (17.2%), polydipsia (10.6%) and constipation (9.0%). Most of them were both mild (90.5%) and possible (59.2%). Constipation was an important cause of withdrawal. Conclusions: Data seems to indicate that 1 mg Mazindol is well tolerated for obesity treatment and its adverse events profile is acceptable. However, it is necessary to emphasize in the use appropriate of the drug, following the dosage schedule and indications approved. Medi c a l S a fe ty & G lo b a l H ea lth

show abstract

Section: Discussionsupporting

confidence: 83%